The Europe Antibiotics Market is witnessing steady growth, driven by the increasing prevalence of infectious diseases, an aging population, and advancements in diagnostic capabilities. These factors ...
France's rising debt, fiscal deficits, and sluggish GDP growth weigh on EWQ ETF performance. See why we rate the ETF a sell ...
Novavax said it was eligible to receive royalties in high teens to low twenties percent on Sanofi sales, up to $350 million ...
Cash position of €7.5 million as of December 31, 2024 BioChaperone Lispro final dosing of Phase 3 triggered a $10 million revenue recognition, and top-line data are expected in mid-2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback